Infection with methicillin-resistant Staphylococcus aureus (MRSA) has reached endemic proportions in the United Kingdom.
Dr David Bowrey and colleagues from England determined the frequency of methicillin-resistant Staphylococcus aureus infection in patients undergoing esophagectomy.
The research team reported on its impact on patient outcomes.
The researchers assessed 98 patients undergoing esophagectomy for carcinoma from 1998 to 2004.
The team collected patient information prospectively, and entered the data into a computerized database.
The data was analyzed retrospectively by univariate and multivariate analysis.
|1 in 5 undergoing esophagectomy developed MRSA|
|World Journal of Surgery|
Overall, the researchers found that 20% developed infection with methicillin-resistant Staphylococcus aureus after esophagectomy.
Patients who developed the infection had greater levels of postoperative morbidity, and longer intensive care unit stays.
The researchers observed that patients with methicillin-resistant Staphylococcus aureus had longer hospital stays.
The team identified preoperative chemotherapy, and readmission to the intensive care unit as a risk factors for the infection.
The researchers noted that 37% who received neoadjuvant chemotherapy developed methicillin-resistant Staphylococcus aureus infection.
Only 6% of those who did not receive neoadjuvant chemotherapy developed methicillin-resistant Staphylococcus aureus.
Dr Bowrey's team concludes, “Overall, 1 in 5 patients undergoing esophagectomy developed methicillin-resistant Staphylococcus aureus infection.”
“Those patients who received neoadjuvant chemotherapy were identified as being at greatest risk of this complication.”
“This is an alarming finding, as neoadjuvant chemotherapy is the standard of care for patients with esophageal carcinoma in the United Kingdom. “